Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.
J Prev Alzheimers DisMay 27, 2026 (epub)
Frank Jessen, Grazia Dell'Agnello, Jennifer A Zimmer et al.
✦ AI-curated · Sources linked
In 30 seconds
This post-hoc analysis of the TRAILBLAZER-ALZ 2 trial evaluated the efficacy and safety of donanemab in European Union-eligible patients with early symptomatic Alzheimer's disease. The study found that donanemab-treated participants had a mean CDR-Sum of Boxes change from baseline that was -0.7 points lower than placebo, indicating significant slowing of disease progression over 76 weeks.
Key findings
- Donanemab-treated participants showed a mean CDR-Sum of Boxes change of -0.7 points compared to placebo.
- There was a 40.3% lower risk of disease progression to the next stage in donanemab-treated participants.
- 19.5% of donanemab-treated participants experienced amyloid-related imaging abnormalities-edema/effusion.
- Safety findings were consistent between the placebo-controlled period and the long-term extension group.
Why it matters
The findings suggest that donanemab may effectively slow the progression of Alzheimer's disease in specific patient populations, providing clinicians with evidence to consider this treatment option in early symptomatic cases.